Navidea Biopharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in the development and commercialization of precision radiopharmaceuticals for molecular imaging and therapy. The company’s proprietary technology platforms are designed to build targeted diagnostic agents that help physicians visualize biological processes at the cellular level, with the goal of improving disease detection, staging and monitoring.
The lead commercial product, Lymphoseek® (technetium Tc 99m tilmanocept), is approved by the U.S. Food and Drug Administration for lymphatic mapping and sentinel lymph node detection in patients with solid tumors. Lymphoseek’s targeted mechanism offers high binding affinity to specific cellular receptors in lymphatic tissue, enabling more accurate localization than traditional blue dyes and radiocolloids. This agent has been adopted in clinical centers across North America to assist in surgical oncology procedures for breast cancer and melanoma.
Beyond its approved product, Navidea maintains a pipeline of novel imaging candidates for oncology, inflammatory disease and neurodegenerative disorders. These candidates leverage the company’s expertise in small-molecule conjugates labeled with radioisotopes suitable for single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Ongoing clinical programs aim to expand the role of targeted radiopharmaceuticals in early disease detection and patient management.
Founded in 2002 and headquartered in Dublin, Ohio, Navidea conducts research, development and manufacturing activities in the United States, serving a global customer base that includes academic medical centers and specialty imaging laboratories. Under the guidance of its executive management team and board of directors, the company continues to advance its precision imaging platforms and seek regulatory approvals for its diagnostic pipeline.
AI Generated. May Contain Errors.
